The U.S. Food and Drug Administration has approved FluMist — the nasal spray flu vaccine — for home use by a patient or adult caregiver. Dr. Nicole Saphier and Dr. Marc Siegel weigh in.

The Food and Drug Administration (FDA) has approved a nasal spray flu vaccine, FluMist, that consumers aged 2 to 49  will be able to administer themselves

A nasal spray flu vaccine for people up to 49 will be available for home use starting in the fall of 2025 after the Food and Drug Administration expanded its approval of AstraZeneca's FluMist. Why it matters: It will be the first flu vaccine that doesn't need to be administered by a health provider and will be sold direct to consumers for home use via an online pharmacy.